News
ProMed Advances Liquid Silicone Rubber Molding for High-Precision Medical Devices
ProMed, a leading contract manufacturer specializing in silicone and plastic components for regulated industries, announces significant advancements in liquid silicone rubber molding (LSR) technology tailored to high-precision medical devices. These enhancements are set to reinforce ProMed’s position as a trusted partner for medical device manufacturers seeking reliability, quality, and regulatory compliance in their silicone components. Liquid silicone rubber molding has become a critical process in medical device manufacturing due to its unique combination of biocompatibility, durability, and flexibility. ProMed’s investment in state-of-the-art molding equipment and process optimization techniques ensures that components meet stringent specifications for dimensional accuracy and material purity, key factors in the production of implantable devices, surgical tools, diagnostic equipment, and wearable health technologies. The company’s approach focuses on meticulous control of molding parameters, including injection speed, cure temperature, and pressure profiles. This precision enhances part reproducibility, minimizes defects, and ensures consistent performance across large production volumes. Such consistency is vital in medical applications, where even minor deviations can affect patient safety and device functionality. In addition to technical upgrades, ProMed emphasizes compliance with the rigorous regulatory landscape governing medical silicone components. All molded parts undergo thorough testing and validation in alignment with ISO 10993 biocompatibility standards and USP Class VI certifications. This comprehensive quality assurance process extends through every phase of production, from raw material selection to final inspection, helping customers confidently navigate FDA and international approvals. ProMed’s expertise in LSR molding also includes advanced techniques such as multi-shot molding and over-molding, which enable the creation of complex, multi-material components that improve device ergonomics and functionality. These capabilities support innovation in next-generation medical devices by allowing integrated designs that reduce assembly steps and improve durability. The company’s highly trained engineering and manufacturing teams collaborate closely with customers during product development, offering material selection guidance and design for manufacturability reviews. This partnership approach helps optimize durometer selection and geometric design, balancing flexibility and rigidity to meet specific clinical requirements. Early involvement in the design process reduces tooling complexity and accelerates time-to-market. Material traceability and batch documentation are integral to ProMed’s manufacturing operations. Electronic batch records and lot tracking systems facilitate rapid root cause analysis and support detailed regulatory audits. This level of transparency enhances supply chain reliability and fosters trust among device manufacturers and regulators alike. ProMed’s advancements come amid growing demand for silicone-based medical components capable of withstanding harsh sterilization methods, including steam autoclaving, ethylene oxide, and gamma irradiation. The company’s molded parts maintain mechanical integrity and chemical resistance after repeated sterilization cycles, ensuring long-term performance in critical clinical environments. The company continues to invest in research and development, exploring new silicone formulations and processing technologies that further enhance product performance while controlling costs. Emphasis on lean manufacturing and continuous quality improvement enables ProMed to deliver high-value solutions without compromising compliance or reliability. As medical device manufacturers face increasingly complex regulatory challenges and market pressures, ProMed’s expanded capabilities in liquid silicone rubber molding provide a competitive edge through precision, consistency, and robust quality systems. This advancement underscores the company’s commitment to supporting the evolving needs of the healthcare industry with innovative manufacturing solutions designed to improve patient outcomes and device reliability. For medical device companies seeking a manufacturing partner that combines deep expertise with flexible, scalable production capabilities, ProMed’s leadership in LSR molding represents a compelling option. The company’s comprehensive service offering extends from prototyping and small-batch runs to high-volume production, making it well-suited for both established products and emerging technologies. By continuously pushing the boundaries of what is possible in medical-grade silicone molding, ProMed remains dedicated to delivering components that meet the highest standards of purity, precision, and performance required in the most demanding healthcare applications. About ProMed: Since 1989, ProMed has been recognized as a leading Contract Manufacturer of complex, intricately designed molded silicone and plastic components and assemblies for highly regulated industries. ProMed’s expertise extends across applications for short-term and long-term implantable devices, drug-releasing combination devices, and specialized materials and processes for aerospace, defense, and automotive applications. We collaboratively work with our customers from prototype through production, providing over 30 years of experience related to design for manufacturability, material selection, tool and fixture design, process development, manufacturing, and other value-added services that result in cost-effective solutions with superior quality.
Ayham Chaban Wins a 2025 Global Recognition Award for Excellence in Leadership, Innovation, and Global Dental Industry Transformation
RPT Labs Brings Fast, Reliable Drug Testing to Boston Communities
RPT Labs Supports Safer Hiring With Drug Screening in Braintree
- July 2, 2025Medicine & Pharmaceuticals
MDC Associates to Showcase Regulatory and Clinical Expertise at ADLM 2025
MDC Associates, a premier regulatory and clinical consulting firm specializing in in vitro diagnostics (IVDs) and medical devices, will attend ADLM 2025 —the leading laboratory medicine conference formerly known as the AACC Annual Meeting. The event convenes from July 27 to 31, 2025, at McCormick Place Convention Center in Chicago, with exhibits running from July 29 to 31. With over 35 years of experience supporting startups and global organizations, MDC Associates remains dedicated to advancing diagnostic innovation through expert regulatory strategy, clinical study design, and quality system compliance. MDC Associates offers comprehensive services designed to help diagnostic developers navigate complex regulatory frameworks, including FDA 510(k), De Novo, PMA, and IVDR submissions. The firm’s approach emphasizes early and strategic engagement through FDA Q-submissions to mitigate risks and accelerate review processes. Clients benefit from tailored quality management system implementation, audit preparation, and complaint handling to ensure smooth pathways to market across multiple regulatory jurisdictions. At ADLM 2025 , MDC Associates will connect with laboratory medicine professionals, device manufacturers, and regulatory authorities to share insights on critical industry topics. Key themes expected to be discussed include evolving IVDR requirements, the growing role of point-of-care and home-use diagnostics, and innovative approaches to clinical evidence generation. Participation in this event reinforces MDC Associates’ role as a trusted partner in helping clients respond to the changing landscape with clarity and confidence. The company’s clinical research organization (CRO) services will also be a focus at the conference. MDC Associates designs and manages clinical, analytical, and usability studies that validate diagnostic performance and support regulatory submissions. Their expertise spans molecular diagnostics, antigen/antibody testing, companion diagnostics, and emerging technologies like next-generation sequencing and digital imaging. By integrating clinical and regulatory strategy, MDC Associates ensures that data quality and regulatory readiness align seamlessly. MDC Associates prioritizes clear, accessible communication, guiding clients through each phase of product development without overwhelming technical jargon. Whether assisting early-stage startups or multinational developers, the company sets realistic expectations for study timelines, resource allocation, and regulatory milestones. This transparency helps clients plan effectively and avoid costly delays. Beyond individual projects, MDC Associates fosters industry education through resources and training that clarify regulatory and quality requirements. This empowers innovators to anticipate challenges such as CLIA waiver study needs or MDR audit preparations and to implement effective strategies proactively. The firm’s multidisciplinary teams work collaboratively across regulatory affairs, quality systems, clinical operations, and data management. This integrated approach, supported by robust project management, ensures submissions and clinical programs progress smoothly, maximizing the likelihood of successful product approval. MDC Associates’ attendance at ADLM 2025 highlights its dedication to supporting diagnostic companies in a dynamic and competitive environment. The event provides a valuable platform to exchange knowledge, explore regulatory developments, and build partnerships that drive innovation forward. Diagnostic innovators seeking expert regulatory and clinical consulting are encouraged to connect and learn how MDC Associates can help streamline their path to market. About MDC Associates: MDC provides life-saving diagnostic makers with the right support and catered solutions needed to make our world a healthier place. With over 35 years of experience, MDC Associates has the experience and expertise to provide unparalleled regulatory strategy and execution, full-service CRO planning and study management, quality systems design and implementation, and data management support, guidance, and analysis. Located on the technology corridor north of Boston, Massachusetts, MDC has earned a reputation of trust with companies of all sizes that develop, manufacture, and distribute in vitro diagnostic tests and instruments. The unique way MDC focuses its work and counsel guides clients in demonstrating safety and efficacy to achieve product approval, making MDC a valuable partner on the path to commercial success.
- June 28, 2025Medicine & Pharmaceuticals
OnSkin App Announces Advises on Salicylic Acid for Acne & Rosacea
Smart skincare product scanner OnSkin has released tips on chemical exfoliation for their users with acne-prone skin who also experience rosacea flare-ups. The overview addresses common misconceptions about chemical exfoliants and offers OnSkin users ingredient-led strategies for managing both conditions. Salicylic acid , a beta-hydroxy acid (BHA) , is a popular choice for acne treatment, widely used for its exfoliating and anti-inflammatory properties. It works by dissolving excess oil and breaking down the bonds between dead skin cells. However, its potential for dryness and irritation raises questions among those with rosacea, a chronic inflammatory skin condition. While BHA can help reduce redness, acne-causing bacteria, and clogged pores, higher concentrations or frequent use may disrupt the skin barrier and trigger rosacea flare-ups. In its new resource, OnSkin not only answers the question “ What is salicylic acid ?” but also breaks down the risks of improper use for people with sensitive skin and offers alternative, more gentle treatments. The guide recommends: Consulting a dermatologist before adding any new active treatment Patch-testing new products Pairing exfoliating acids with ingredients like ceramides and niacinamide Avoiding mechanical scrubs and harsh alcohols Double-checking the ingredients with a rosacea ingredient checker OnSkin also highlights azelaic acid as a commonly recommended, gentler alternative that offers similar acne-fighting benefits with a lower likelihood of irritation. Both over-the-counter formulas (up to 10%) and prescription options (at 15%–20%) can help manage rosacea and mild to moderate acne. The article emphasizes the importance of ingredient literacy and product compatibility, urging users to carefully research all new formulations and consider professional guidance when dealing with multiple inflammatory conditions. This update is part of OnSkin’s broader mission of informing and educating its users about beauty products and making skincare accessible. About OnSkin OnSkin skincare scanner is an app that analyzes beauty products and offers personalized, science-based recommendations. The app generates a safety score based on the safety of the ingredients and helps users choose the best products for their skin type. OnSkin empowers users to understand their beauty products and make informed decisions that align with their skincare goals.
- June 25, 2025Medicine & Pharmaceuticals
ProMed Elevates Standards in Medical Device Silicone Molding for Next-Generation Therapies
As demand rises for precision-engineered components in advanced therapeutic applications, ProMed is setting a higher bar for quality and performance in medical device silicone molding . With more than three decades of experience serving regulated industries, the company is expanding its capabilities to better support the next wave of innovation in medical, pharmaceutical, and combination device development. Known for its work in short- and long-term implantable devices, drug-releasing technologies, and customized molding solutions, ProMed continues to invest in materials expertise, in-house tooling, and highly controlled manufacturing environments. The company’s commitment to meeting the evolving needs of OEMs and startups alike has positioned it as a trusted partner for some of the most complex and compliance-driven molding projects in healthcare. Recent advancements at ProMed include the integration of enhanced automation systems, expanded capacity in Class 7 cleanroom environments, and new process controls aimed at supporting tighter tolerances and greater consistency across high-volume runs. These developments not only reduce time to market but also improve scalability for customers preparing to launch novel therapies and drug-device combinations. At the core of ProMed’s value is its ability to manage silicone molding projects from prototype through production, providing engineering support, tool design, material selection, and manufacturing under one roof. The company’s development center in Plymouth, MN, plays a key role in accelerating design for manufacturability (DFM) efforts while maintaining traceability and quality across all stages of production. ProMed’s deep understanding of elastomeric materials—including both Liquid Silicone Rubber (LSR) and High Consistency Rubber (HCR)—remains essential in creating devices that demand chemical stability, biocompatibility, and performance under dynamic biological conditions. With durometer ranges from 10 to 80 Shore A and shot size capabilities from 0.5ccm to 180ccm, the company is equipped to support a broad spectrum of device types, from micro-molded drug delivery implants to larger over-molded surgical components. In the realm of medical device silicone molding , precision is not just a technical requirement—it’s a regulatory imperative. ProMed maintains ISO 13485 certification, FDA registration, and ITAR compliance, ensuring that all products meet or exceed quality management expectations. Cross-functional teams of engineers, quality professionals, and manufacturing specialists collaborate closely to preserve dimensional stability and material integrity throughout the product lifecycle. This approach has been especially valuable in supporting combination devices, which require seamless integration of pharmaceutical ingredients with device substrates. ProMed offers specialized expertise in achieving desired drug release profiles using silicone as a controlled-release medium, helping to bridge the gap between traditional device design and pharmaceutical efficacy. The company’s pharma-dedicated facility in Maple Grove, MN, and expanded operations in Dorado, Puerto Rico, further strengthen these capabilities. In addition to its technical capabilities, ProMed remains committed to sustainable manufacturing practices. Strategic use of materials, waste reduction initiatives, and supply chain reliability are built into each program, offering long-term value to partners navigating complex markets and tight regulatory windows. As innovation in MedTech and pharma continues to accelerate, ProMed’s tailored approach to silicone molding stands out. Whether supporting a startup's first prototype or helping a global OEM scale up production for a new therapy, the company delivers consistency, reliability, and deep industry insight. With a structured organization designed to handle critical projects from concept to completion, ProMed remains focused on one goal: enabling the future of healthcare through smart, scalable, and compliant silicone molding solutions. About ProMed: Since 1989 ProMed has been recognized as a leading Contract Manufacturer of complex, intricately designed molded silicone and plastic components and assemblies for highly regulated industries. ProMed’s expertise extends across applications for short-term and long-term implantable devices, drug-releasing combination devices, and specialized materials and processes for aerospace, defense, and automotive applications. We collaboratively work with our customers from prototype through production, providing over 30 years of experience related to design for manufacturability, material selection, tool and fixture design, process development, manufacturing, and other value-added services that result in cost-effective solutions with superior quality.
- June 25, 2025Medicine & Pharmaceuticals
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
NEW YORK – June 25th, 2025 – Silo Pharma, Inc. ( Nasdaq: SILO ) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.“With obesity at epidemic levels and no curative therapies available, we believe the VA’s biologic GDNF is potentially a game-changer,” said Eric Weisblum, CEO of Silo Pharma. “We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials.” “This VA-originated obesity technology has the potential to disrupt a $16 billion market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders,” added Robb Knie, CEO of Hoth Therapeutics. “We are proud to partner with Silo Pharma in an effort to bring this innovation to the public.” Deal Highlights: Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use. 50/50 joint venture structure with equal equity and governance participation. Lead indication: Obesity and NAFLD — conditions with prevalence among both civilian and veteran populations. Unmet Need: Obesity affects over 40% of U.S. adults and is a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care. There are no approved curative biologics targeting the neuroinflammatory root of obesity, a gap that this VA-originated technology is uniquely positioned to fill. Strategic Alignment: The partnership leverages: The clinical infrastructure and public mission of the VA Hoth’s regulatory and development expertise Silo’s translational capabilities and capital efficiency About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law. Source: SILO Pharma Inc. Contact 800-705-0120 [email protected]
- June 25, 2025Medicine & Pharmaceuticals
MDC Associates Sets New Standard in Clinical Trial Management for In Vitro Diagnostics
MDC Associates, a consultancy specializing in regulatory, quality, and clinical solutions for in vitro diagnostics (IVDs) and medical devices, is working to reshape the landscape of clinical trial management . With over 35 years of expertise and a proven track record of supporting over 700 IVD and MedTech clients worldwide, the company is setting a new benchmark for excellence in navigating the complex process of bringing diagnostic innovations to market. The demand for reliable and efficient clinical trial management continues to grow as the healthcare industry advances. For IVD and medical device companies, ensuring compliance with regulatory standards while expediting time-to-market is critical. MDC Associates is meeting this challenge with a comprehensive suite of services tailored to the unique needs of IVD manufacturers. By offering strategic guidance and hands-on support, the company is helping innovators transform groundbreaking ideas into life-saving products. MDC Associates’ clinical trial management services cover every process stage, from initial study design to final reporting. This includes developing clinical, analytical, and usability study protocols that adhere to stringent regulatory requirements. The firm identifies and qualifies study sites, manages contracts, and oversees Institutional Review Board (IRB) processes, ensuring studies are conducted efficiently and ethically. Through meticulous study monitoring, data management, and analysis, MDC delivers actionable insights and robust documentation that facilitate smooth regulatory submissions. The firm’s expertise spans various diagnostic applications, including microbiology, infectious diseases, clinical chemistry, oncology, and companion diagnostics. Its experience with diverse technologies such as molecular diagnostics, next-generation sequencing, mass spectrometry, and digital imaging positions MDC Associates as a trusted partner for companies developing cutting-edge solutions. This broad technical knowledge enables the firm to anticipate challenges and devise strategies that mitigate risks, optimize resources, and maintain compliance with regulatory standards. MDC Associates’ success in clinical trial management is reflected in its impressive track record. The company has conducted over 100 clinical studies across the United States and Europe, managed over 140 FDA submissions, and supported approximately 520 FDA Q-submissions annually. This extensive experience gives clients confidence in their regulatory journey, knowing that every detail is handled with precision and expertise. Regulatory compliance is a cornerstone of clinical trial management, and MDC Associates excels in navigating the complex regulatory landscape. The firm’s services include preparing comprehensive submission packages for 510(k), De Novo, and PMA applications and obtaining CE/IVDR certifications for European markets. Its expertise in FDA Breakthrough Device Designation and Q-submission management further underscores its ability to secure timely regulatory approvals for innovative diagnostics. As the healthcare industry evolves, MDC Associates remains at the forefront of clinical trial management for IVDs. The firm’s commitment to innovation, excellence, and client success has established it as a leader in the field. MDC is playing a vital role in advancing healthcare by guiding diagnostic companies through the regulatory maze and helping them bring their products to market efficiently. MDC Associates is headquartered in Boston, with consultants strategically located across the United States and Europe to provide localized support. For more information on the company’s clinical trial management services and other offerings, visit http://mdcassoc.com About MDC Associates: MDC provides life-saving diagnostic makers with the right support and catered solutions needed to make our world a healthier place. With over 35 years of experience, MDC Associates has the experience and expertise to provide unparalleled regulatory strategy and execution, full-service CRO planning and study management, quality systems design and implementation, and data management support, guidance, and analysis. Located on the technology corridor north of Boston, Massachusetts, MDC has earned a reputation of trust with companies of all sizes that develop, manufacture, and distribute in vitro diagnostic tests and instruments. The unique way MDC focuses its work and counsel guides clients in demonstrating safety and efficacy to achieve product approval, making MDC a valuable partner on the path to commercial success.
- June 25, 2025Medicine & Pharmaceuticals
MDC Associates Enhances IVD Clinical Trial Design to Accelerate Regulatory Approval
MDC Associates, a leading consultancy specializing in in vitro diagnostic (IVD) clinical trial design and regulatory strategy, has introduced innovative enhancements to its clinical trial planning process. These advancements aim to streamline regulatory approval pathways, reduce time to market, and improve the overall efficiency of clinical trials for diagnostic manufacturers. The in vitro diagnostic industry continues to evolve rapidly, with new technologies and methodologies reshaping the landscape of disease detection and patient care. As regulatory expectations tighten and competition grows, diagnostic companies face increasing challenges in designing trials that efficiently demonstrate clinical validity and utility. MDC Associates is addressing these challenges with a more refined approach to clinical trial design that integrates strategic regulatory insights, data-driven methodologies, and adaptive trial frameworks. By incorporating real-world evidence, advanced data analytics, and strategic site selection, the enhanced clinical trial framework maximizes efficiency while ensuring compliance with evolving regulatory requirements. This approach helps diagnostic companies mitigate risks, address potential regulatory concerns earlier in the process, and provide robust data packages that facilitate faster regulatory review. Key aspects of the enhanced IVD clinical trial design include optimized patient recruitment strategies, streamlined protocol development, and proactive regulatory engagement. MDC Associates leverages predictive modeling to identify optimal study populations and ensure diversity in clinical trials, resulting in data sets that more accurately reflect real-world clinical performance. Additionally, the company’s regulatory experts provide early-stage guidance to help clients anticipate regulatory feedback and adapt trial designs accordingly. Strategic site selection remains a cornerstone of the enhanced process, ensuring that trials are conducted in facilities with the appropriate expertise, patient populations, and logistical support to meet regulatory expectations. By prioritizing sites with a history of high-quality data collection and regulatory compliance, MDC Associates enhances the credibility and reliability of study outcomes. Adaptive trial designs play a crucial role in reducing timelines and increasing flexibility within the regulatory process. MDC Associates employs adaptive methodologies that allow for real-time data analysis and modifications to study protocols without compromising regulatory integrity. This dynamic approach enables more efficient trial execution and minimizes costly delays associated with traditional, rigid clinical trial structures. The company’s expanded focus on data analytics also plays a pivotal role in refining trial design. Leveraging machine learning and artificial intelligence, MDC Associates enables more precise endpoint selection, reduces data variability, and enhances overall trial efficiency. These innovations not only accelerate approval timelines but also contribute to more robust and reliable diagnostic products reaching the market faster. With increasing pressure on diagnostic manufacturers to meet stringent regulatory requirements while maintaining commercial viability, a well-structured clinical trial strategy is more critical than ever. MDC Associates’ latest advancements ensure that clients are well-positioned to navigate the complex regulatory landscape while bringing innovative diagnostic solutions to market in an expedited and cost-effective manner. As regulatory agencies continue to emphasize patient-centric outcomes and evidence-based decision-making, diagnostic companies require expert guidance to align their clinical trial strategies with these expectations. MDC Associates’ commitment to innovation and excellence in clinical trial design provides a significant advantage for companies looking to accelerate regulatory approval and achieve commercial success. MDC Associates is headquartered in Boston, with consultants strategically located across the United States and Europe to provide localized support. For more information on the company’s clinical trial management services and other offerings, visit http://mdcassoc.com . About MDC Associates: MDC provides life-saving diagnostic makers with the right support and catered solutions needed to make our world a healthier place. With over 35 years of experience, MDC Associates has the experience and expertise to provide unparalleled regulatory strategy and execution, full-service CRO planning and study management, quality systems design and implementation, and data management support, guidance, and analysis. Located on the technology corridor north of Boston, Massachusetts, MDC has earned a reputation of trust with companies of all sizes that develop, manufacture, and distribute in vitro diagnostic tests and instruments. The unique way MDC focuses its work and counsel guides clients in demonstrating safety and efficacy to achieve product approval, making MDC a valuable partner on the path to commercial success.
- June 25, 2025Medicine & Pharmaceuticals
MDC Associates Expands MedTech Clinical Solutions to Accelerate Regulatory Success
MDC Associates, a leading provider of clinical and regulatory consulting services for the MedTech industry, has announced a significant expansion of its MedTech clinical solutions designed to help medical device companies navigate the regulatory landscape more efficiently. The initiative aims to streamline the pathway from product development to market clearance, ensuring that innovators can bring life-changing technologies to patients faster and with greater confidence. The evolving regulatory landscape presents both challenges and opportunities for MedTech companies. With increasing scrutiny from regulatory bodies such as the FDA, EMA, and other global health authorities, the need for precise, well-documented clinical evidence has never been greater. The expanded suite of solutions offered by MDC Associates addresses these complexities by providing comprehensive support in clinical trial design, regulatory strategy, data analysis, and submission preparation. The new MedTech clinical solutions include enhanced clinical trial management services, regulatory submission optimization, and advanced real-world evidence (RWE) strategies. These additions are designed to mitigate delays, improve submission quality, and align clinical development efforts with regulatory expectations. By leveraging cutting-edge data analytics and a deep understanding of evolving regulatory requirements, MDC Associates empowers MedTech companies to reduce risk and accelerate time to market. A key component of this expansion is the integration of digital tools and artificial intelligence to improve trial efficiency and data integrity. MDC Associates has invested in proprietary technology that enhances trial monitoring, patient recruitment, and compliance tracking. These innovations help sponsors adapt to the increasing demand for decentralized trials and real-world data collection, providing regulators with more robust and relevant evidence to support device approvals. The expansion also includes strengthened support for startups and mid-sized MedTech firms that may lack in-house regulatory expertise. By offering tailored regulatory roadmaps, gap analyses, and hands-on clinical trial guidance, MDC Associates helps companies of all sizes navigate the intricate approval processes in the U.S., Europe, and other global markets. The firm’s multidisciplinary team of experts works closely with clients to ensure clinical development plans align with long-term business objectives while meeting regulatory requirements. As part of its commitment to advancing MedTech innovation, MDC Associates is also enhancing its educational resources, offering workshops, webinars, and one-on-one consulting sessions to equip clients with the knowledge needed to succeed in an increasingly complex regulatory environment. These initiatives aim to bridge the gap between regulatory expectations and practical implementation, helping companies anticipate and address potential challenges before they impact development timelines. The expanded clinical solutions are available immediately to MedTech companies seeking to optimize their regulatory strategy and clinical trial execution. By providing a more robust, technology-driven approach to clinical development, MDC Associates continues to be a trusted partner in driving regulatory success for innovative medical device companies worldwide. MDC Associates is headquartered in Boston, with consultants strategically located across the United States and Europe to provide localized support. For more information on the company’s clinical trial management services and other offerings, visit http://mdcassoc.com . About MDC Associates: MDC provides life-saving diagnostic makers with the right support and catered solutions needed to make our world a healthier place. With over 35 years of experience, MDC Associates has the experience and expertise to provide unparalleled regulatory strategy and execution, full-service CRO planning and study management, quality systems design and implementation, and data management support, guidance, and analysis. Located on the technology corridor north of Boston, Massachusetts, MDC has earned a reputation of trust with companies of all sizes that develop, manufacture, and distribute in vitro diagnostic tests and instruments. The unique way MDC focuses its work and counsel guides clients in demonstrating safety and efficacy to achieve product approval, making MDC a valuable partner on the path to commercial success.
- June 23, 2025Medicine & Pharmaceuticals
Pharmacy RFP Contract & Cost Management For Senior Living Facilities Announced
With rising costs and tighter regulatory oversight in long-term care, LTC RFP believes pharmacy service contracts deserve a closer look. The company helps facility decision-makers optimize their pharmacy service contracts through a structured RFP process that seeks to improve pricing, compliance, pharmacy responsiveness, and resident care. More information is available at https://ltcrfp.com Skilled nursing and assisted living communities often default to limited pharmacy options due to perceived RFP complexities or fear of disrupting services. However, LTC RFP removes these potential challenges by offering hands-on support through every stage of the pharmacy Request for Proposal (RFP) process. Their mission is to help long-term care administrators and Directors of Nursing better understand pharmacy contracts and how to negotiate the best pricing and services for their needs. "Many long-term care facilities feel “locked in” to large, default pharmacy providers, but failing to evaluate your options opens up many vulnerabilities," says a spokesperson for LTC RFP. "We offer free pharmacy contract reviews and custom RFP guidance to help facilities gain control over pharmacy costs and services." LTC RFP begins by offering a free assessment to review a facility’s current pharmacy contract, pricing structure, and compliance concerns. This step often reveals overlooked fees, missed rebates, or service limitations that may be impacting both budgets and resident care. From there, the firm builds a custom RFP that outlines the community’s specific needs, allowing them to attract pharmacy partners that are a stronger clinical and operational fit. Once proposals are submitted, LTC RFP conducts a thorough evaluation of the options, highlighting differences in cost, responsiveness, and clinical value. For facilities that choose to change providers, LTC RFP also supports the transition planning process, coordinating onboarding and implementation to ensure a seamless switch with no interruptions in medication management. In addition to RFP guidance, the firm offers rebate and billing audits, as well as compliance and medication management consulting. These services are especially important as regulatory policies continue to evolve and medication-related costs remain one of the largest line items for long-term care providers. By identifying risks, inefficiencies, and opportunities, LTC RFP enables decision-makers to align pharmacy services with both care goals and budget constraints. LTC RFP works exclusively with skilled nursing and assisted living facilities, serving as an unbiased advocate for administrators seeking cost-effective, transparent, and compliant pharmacy partnerships and helping leadership secure greater accountability and improved service from pharmacy partners. Learn more by visiting https://ltcrfp.com
- June 17, 2025Medicine & Pharmaceuticals
Pharmamex RX Provides Itravil Pills for Weight Loss in Mexico
Pharmamex RX, a provider of prescription medications in Mexico, provides Itravil pills for weight loss. The medication is available through the company’s online platform and can be used as part of a weight management plan. It is recommended that the use of this medication be guided by a healthcare professional to ensure it is appropriate for individual needs. The representative of Pharmamex RX stated, “Itravil is used in conjunction with a balanced diet and regular physical activity. It functions as an appetite suppressant to help manage food intake as part of a weight management approach.” Itravil pills for weight loss are intended to assist individuals in managing their weight as part of a broader weight control strategy. As with any weight loss medication, it is important to use it appropriately under medical supervision to ensure its proper application. The Itravil pills are available through the Pharmamex RX website, providing a straightforward process for users to access the medication. Itravil is part of Pharmamex RX's range of products designed to aid weight management. While it may help reduce appetite, it should complement a healthy lifestyle rather than replace it. Professional guidance is necessary to ensure the treatment aligns with individual health needs. The firm ensures that all medications, including Itravil pills, meet safety standards when used as part of an overall health plan. These products are intended to be used in conjunction with a balanced diet, exercise, and medical advice. Itravil is available through Pharmamex RX’s online platform, offering a secure method for obtaining the medication. Orders are processed promptly, and delivery is made to customers across Mexico. In addition, Itravil pills are part of the company’s selection of weight loss products that suppress appetite and may help reduce caloric intake. Pharmamex RX also emphasizes addressing any underlying health conditions that may contribute to weight gain. The representative added, “It is important that these medications are used under the supervision of a healthcare provider to ensure they are appropriate for the individual’s needs.” Pharmamex RX provides Itravil pills as part of its range of weight management options, ensuring access to a regulated treatment under medical supervision for individuals managing their weight.
- June 17, 2025Medicine & Pharmaceuticals
PharmaMex RX Offers Effective Solutions For Sleeping Disorders
PharmaMex RX is a leading provider of online medications specifically designed to address sleep disorders. The company strongly emphasizes quality and safety in its product offerings, ensuring that every medication it provides meets the required standards for effectiveness and reliability. Their dedication to selecting the best possible treatments is evident in the solutions they offer for individuals suffering from various sleep-related issues. The representative at the PharmaMex RX stated, "Our mission is to provide our customers with reliable, quality solutions that help them address their sleep disturbances safely and effectively." The company's sleep disorder treatment approach focuses on providing reliable products that deliver measurable results. Their team of experts ensures that only trusted, results-producing medications are provided to customers. This approach simplifies the decision-making process for individuals seeking practical solutions for types of sleep disorders. One of the most commonly ordered medications is Farmapram alprazolam tablets. These tablets are designed to manage sleep disturbances caused by anxiety, helping individuals fall asleep and maintain restful sleep throughout the night. By addressing the symptoms and causes of sleep problems, Farmapram allows for improved sleep quality without unnecessary complications. PharmaMex RX's offerings directly improve the quality of life for individuals affected by sleep disorders. The company's focus on selecting effective, safe medications helps individuals to address their sleep issues confidently, knowing that they are using products carefully vetted for both safety and effectiveness. The firm's representative added, "We are committed to ensuring that every product we offer is trusted so individuals can make the best decisions for their health and well-being." The company focuses on providing reliable medication for sleeping disorders that meet established standards for quality and safety. PharmaMex RX continues to serve individuals seeking solutions for sleep-related issues with results-oriented products.
- June 17, 2025Medicine & Pharmaceuticals
PharmaMex Adds Lexotan Bromazepam Tablets to Its Medication Lineup
PharmaMex, a leading pharmaceutical distributor committed to quality and patient-focused accessibility, has made Lexotan Bromazepam 3 mg tablets available for individuals managing specific mental health conditions. This step reflects the company's broader goal of enhancing the availability of essential medications that meet diverse treatment needs across the region. Lexotan, known generically as bromazepam, is classified within the benzodiazepine group of medicines and is primarily used in the management of anxiety, tension, and agitation. This medication affects brain chemicals that are believed to influence mood and stress response. Each pack contains 30 tablets, and its use is intended for short-term treatment under direct medical supervision. “Lexotanil 3mg tablets address a therapeutic area that often requires careful clinical consideration,” said a PharmaMex spokesperson. “We understand the importance of access to trusted options like Lexotan for those managing anxiety-related conditions, and we ensure our supply chain maintains the integrity, authenticity, and regulatory compliance of each product we provide.” Lexotan is a prescription-only medicine and is not suitable for anxiety or tension stemming from routine stressors of daily life. It should only be taken as directed by a licensed healthcare professional, as long-term use is typically discouraged. Patients are urged to consult their prescribing physician to determine if the treatment is appropriate for their condition. PharmaMex continues to strengthen its commitment to distributing well-established pharmaceutical products. This includes providing accurate information about medications such as Lexotan Bromazepam and ensuring transparency in sourcing and availability. The company also emphasizes that individuals seeking online Lexotan Bromazepam 3mg medicine must do so through proper medical channels and verified outlets to prioritize patient safety. “As with any benzodiazepine, appropriate medical guidance is critical,” the spokesperson added. “We aim to support healthcare providers by making reliable treatments available while respecting all prescription requirements and promoting responsible use.” Patients and healthcare professionals seeking a Lexotan bromazepam tablet in Mexico are advised to obtain it through licensed pharmacies and with a valid medical prescription, in accordance with local pharmaceutical regulations. PharmaMex reiterates its focus on providing quality, legitimate pharmaceuticals with an emphasis on accessibility and patient well-being. All products, including Lexotan, are sourced in compliance with applicable standards and are intended strictly for prescribed medical use.
ALL NEWS
- Fitliva Introduces the Pilates Stick Deluxe Kit for Convenient and Affordable At-Home Wellness
- Inspectra Edge: A Blueprint for Achieving Superior Quality and Operational Efficiency in the 21st Century
- The Story Behind Testlify: Building for Better Hiring Decisions
- Food Journal Magazine Launches as the Ultimate Guide for Culinary Enthusiasts & Food Festivals
- ICS Health Services Pakistan: Healing with Dignity, Bridging Healthcare and Humanity
- Rameez Ghayas Usmani, Founder of Outreaching.io Awarded as “Best HARO Link Building Expert in the US”
- Ancient Remedies Tops 300,000 Books sold, Launches Kitchen-Ready Healing Guides
- Clutch Names DigiNeat Smart Technologies LLC as the Leading “Internet of Things” Software Development Company in L.A.
- Talents elevate Xiamen: 2025 Talent Service Month launched
- Clearwater Mold Testing & Lab Analysis: Licensed Inspector Services Expanded
- Insectropolis, A Cool Place Visit As The Summer Heats Up At The Jersey Shore
- Digital Storybooks Connect Kids with Family—and Communities Globally
- Top Estate Planning Attorney Bobby Sawyer Discloses Costly Probate Mistakes Executors Should Avoid – Gastonia, North Carolina
- Author Margaret Liu Collins Offers an Uplifting Read in “God is Good: Revised Second Edition,” Filled with Biblically Sourced Advice For Everyone
- How the Library Management Software from Ex Libris Transforms Librarian Workflows and Reduces Administrative Burden
- San Pedro De Alcantara Dental Implants: Same-Day Procedure Announced
- AI SEO Agency Outlines Essential E-E-A-T Authority Signals In New Guide Launch
- Best mini PC 2025 : BOSGAME unveils new M5 AI Mini PC available for Pre-Order
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now